drugset / Trial / NCT00527761
Taxotere/Temodar/Cisplatin Study in Melanoma Patients
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary Objective: 1\. To determine the maximum tolerated dose of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma. Secondary Objectives: 1. To determine the toxicity of chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma 2. To determine the response rate of induction chemotherapy using Taxotere, Temodar, Cisplatin (TTC) in patients with metastatic melanoma.
Timeline
- Start
- 2004-08
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 20 mg | Intravenous |
| Subject | Docetaxel | Small molecule | 20 mg | Intravenous |
| Subject | Temozolomide | Small molecule | 150 mg | Oral |